NASDAQ : DFTX

Definium Therapeutics, Inc. — Company profile

United States

Last price 37.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.10B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Details

NameDefinium Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees106
CeoRobert Barrow
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinCA24477V1058
Cusip24477V105
Cik0001813814

Key executives

NameTitle
Robert BarrowChief Executive Officer and Director
Brandi L. Roberts CPA, M.B.A.Chief Financial Officer
Dr. Daniel Rollings Karlin M.A., M.D.Chief Medical Officer
Dr. Scott M. Freeman M.D.Co-Founder and Clinical Advisor
Leonard LatchmanCo-Founder
Peter MackSenior Vice President of Pharmaceutical Development and Operations
Gitanjali Jain OgawaVice President and Head of Investor Relations
Mark R. Sullivan J.D.Chief Legal Officer and Corporate Secretary
Beth CalitriVice President of Corporate Communications
Stephanie Fagan M.S.Chief Corporate Affairs Officer

Contact

AddressOne World Trade Center, Suite 8500, New York, New York 10007, United States
Phone212 220 6633
Websitehttps://definiumtx.com